Annual EBITDA
$916.70 M
+$351.40 M+62.16%
December 31, 2023
Summary
- As of February 7, 2025, DXCM annual EBITDA is $916.70 million, with the most recent change of +$351.40 million (+62.16%) on December 31, 2023.
- During the last 3 years, DXCM annual EBITDA has risen by +$539.90 million (+143.29%).
- DXCM annual EBITDA is now at all-time high.
Performance
DXCM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
$237.40 M
-$7.30 M-2.98%
September 30, 2024
Summary
- As of February 7, 2025, DXCM quarterly EBITDA is $237.40 million, with the most recent change of -$7.30 million (-2.98%) on September 30, 2024.
- Over the past year, DXCM quarterly EBITDA has dropped by -$7.30 million (-2.98%).
- DXCM quarterly EBITDA is now -21.81% below its all-time high of $303.60 million, reached on December 31, 2023.
Performance
DXCM Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
$975.30 M
-$56.10 M-5.44%
September 30, 2024
Summary
- As of February 7, 2025, DXCM TTM EBITDA is $975.30 million, with the most recent change of -$56.10 million (-5.44%) on September 30, 2024.
- Over the past year, DXCM TTM EBITDA has dropped by -$56.10 million (-5.44%).
- DXCM TTM EBITDA is now -5.44% below its all-time high of $1.03 billion, reached on June 30, 2024.
Performance
DXCM TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
DXCM EBITDA Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
---|---|---|---|
1 y1 year | +62.2% | -3.0% | -5.4% |
3 y3 years | +143.3% | +114.5% | +63.0% |
5 y5 years | +1327.2% | +114.5% | +63.0% |
DXCM EBITDA Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
---|---|---|---|---|---|---|---|
3 y | 3-year | at high | +142.8% | -21.8% | +458.6% | -5.4% | +157.6% |
5 y | 5-year | at high | +330.0% | -21.8% | +458.6% | -5.4% | +357.5% |
alltime | all time | at high | +1327.2% | -21.8% | +248.3% | -5.4% | +1219.8% |
DexCom EBITDA History
Date | Annual | Quarterly | TTM |
---|---|---|---|
Sep 2024 | - | $237.40 M(-3.0%) | $975.30 M(-5.4%) |
Jun 2024 | - | $244.70 M(+29.1%) | $1.03 B(+3.6%) |
Mar 2024 | - | $189.60 M(-37.5%) | $995.60 M(+8.6%) |
Dec 2023 | $916.70 M(+62.2%) | $303.60 M(+3.4%) | $916.70 M(+16.4%) |
Sep 2023 | - | $293.50 M(+40.5%) | $787.30 M(+15.1%) |
Jun 2023 | - | $208.90 M(+88.7%) | $683.80 M(+14.3%) |
Mar 2023 | - | $110.70 M(-36.5%) | $598.50 M(+5.7%) |
Dec 2022 | $565.30 M(+49.7%) | $174.20 M(-8.3%) | $566.10 M(+30.3%) |
Sep 2022 | - | $190.00 M(+53.7%) | $434.40 M(+11.9%) |
Jun 2022 | - | $123.60 M(+57.9%) | $388.20 M(-0.5%) |
Mar 2022 | - | $78.30 M(+84.2%) | $390.00 M(+3.0%) |
Dec 2021 | $377.60 M(+0.2%) | $42.50 M(-70.4%) | $378.60 M(-18.1%) |
Sep 2021 | - | $143.80 M(+14.7%) | $462.40 M(+5.9%) |
Jun 2021 | - | $125.40 M(+87.4%) | $436.50 M(+11.1%) |
Mar 2021 | - | $66.90 M(-47.0%) | $392.90 M(+4.3%) |
Dec 2020 | $376.80 M(+76.7%) | $126.30 M(+7.1%) | $376.80 M(+0.6%) |
Sep 2020 | - | $117.90 M(+44.1%) | $374.40 M(+13.4%) |
Jun 2020 | - | $81.80 M(+61.0%) | $330.30 M(+24.3%) |
Mar 2020 | - | $50.80 M(-59.0%) | $265.80 M(+24.7%) |
Dec 2019 | $213.20 M(-385.4%) | $123.90 M(+67.9%) | $213.20 M(-401.1%) |
Sep 2019 | - | $73.80 M(+326.6%) | -$70.80 M(-18.7%) |
Jun 2019 | - | $17.30 M(-1061.1%) | -$87.10 M(+37.6%) |
Mar 2019 | - | -$1.80 M(-98.9%) | -$63.30 M(-15.3%) |
Dec 2018 | -$74.70 M(+279.2%) | -$160.10 M(-378.4%) | -$74.70 M(-172.6%) |
Sep 2018 | - | $57.50 M(+39.9%) | $102.90 M(+99.0%) |
Jun 2018 | - | $41.10 M(-411.4%) | $51.70 M(+1515.6%) |
Mar 2018 | - | -$13.20 M(-175.4%) | $3.20 M(-116.2%) |
Dec 2017 | -$19.70 M(-60.0%) | $17.50 M(+177.8%) | -$19.70 M(-51.1%) |
Sep 2017 | - | $6.30 M(-185.1%) | -$40.30 M(-33.8%) |
Jun 2017 | - | -$7.40 M(-79.5%) | -$60.90 M(-12.5%) |
Mar 2017 | - | -$36.10 M(+1064.5%) | -$69.60 M(+41.5%) |
Dec 2016 | -$49.20 M(+6.3%) | -$3.10 M(-78.3%) | -$49.20 M(+18.8%) |
Sep 2016 | - | -$14.30 M(-11.2%) | -$41.40 M(-38.0%) |
Jun 2016 | - | -$16.10 M(+2.5%) | -$66.80 M(+29.2%) |
Mar 2016 | - | -$15.70 M(-434.0%) | -$51.70 M(+11.7%) |
Dec 2015 | -$46.30 M(+253.4%) | $4.70 M(-111.8%) | -$46.30 M(-1.5%) |
Sep 2015 | - | -$39.70 M(+3870.0%) | -$47.00 M(+365.3%) |
Jun 2015 | - | -$1.00 M(-90.3%) | -$10.10 M(-22.3%) |
Mar 2015 | - | -$10.30 M(-357.5%) | -$13.00 M(-0.8%) |
Dec 2014 | -$13.10 M | $4.00 M(-242.9%) | -$13.10 M(-25.1%) |
Sep 2014 | - | -$2.80 M(-28.2%) | -$17.50 M(-6.9%) |
Jun 2014 | - | -$3.90 M(-62.5%) | -$18.80 M(-19.0%) |
Date | Annual | Quarterly | TTM |
---|---|---|---|
Mar 2014 | - | -$10.40 M(+2500.0%) | -$23.20 M(+5.9%) |
Dec 2013 | -$21.90 M(-55.3%) | -$400.00 K(-90.2%) | -$21.90 M(-21.8%) |
Sep 2013 | - | -$4.10 M(-50.6%) | -$28.00 M(-28.4%) |
Jun 2013 | - | -$8.30 M(-8.8%) | -$39.10 M(-11.1%) |
Mar 2013 | - | -$9.10 M(+40.0%) | -$44.00 M(-10.4%) |
Dec 2012 | -$49.00 M(+19.8%) | -$6.50 M(-57.2%) | -$49.10 M(-8.6%) |
Sep 2012 | - | -$15.20 M(+15.2%) | -$53.71 M(+5.8%) |
Jun 2012 | - | -$13.20 M(-7.0%) | -$50.79 M(+15.3%) |
Mar 2012 | - | -$14.20 M(+27.8%) | -$44.06 M(+7.7%) |
Dec 2011 | -$40.90 M(-20.3%) | -$11.11 M(-9.5%) | -$40.90 M(+4.9%) |
Sep 2011 | - | -$12.28 M(+89.7%) | -$38.99 M(-1.1%) |
Jun 2011 | - | -$6.47 M(-41.4%) | -$39.43 M(-10.1%) |
Mar 2011 | - | -$11.04 M(+20.0%) | -$43.86 M(-14.5%) |
Dec 2010 | -$51.30 M(+19.0%) | -$9.20 M(-27.7%) | -$51.30 M(+0.5%) |
Sep 2010 | - | -$12.73 M(+16.7%) | -$51.06 M(+3.7%) |
Jun 2010 | - | -$10.90 M(-41.0%) | -$49.23 M(-3.5%) |
Mar 2010 | - | -$18.47 M(+106.2%) | -$51.02 M(+18.4%) |
Dec 2009 | -$43.11 M(-13.4%) | -$8.96 M(-17.8%) | -$43.11 M(-7.4%) |
Sep 2009 | - | -$10.90 M(-14.1%) | -$46.53 M(-4.6%) |
Jun 2009 | - | -$12.69 M(+20.1%) | -$48.77 M(+0.1%) |
Mar 2009 | - | -$10.56 M(-14.7%) | -$48.70 M(-2.2%) |
Dec 2008 | -$49.79 M(+14.9%) | -$12.38 M(-5.8%) | -$49.79 M(+2.8%) |
Sep 2008 | - | -$13.14 M(+4.2%) | -$48.44 M(+5.2%) |
Jun 2008 | - | -$12.62 M(+8.3%) | -$46.03 M(+4.2%) |
Mar 2008 | - | -$11.65 M(+5.6%) | -$44.16 M(+1.9%) |
Dec 2007 | -$43.34 M(-7.0%) | -$11.03 M(+2.8%) | -$43.34 M(+0.8%) |
Sep 2007 | - | -$10.73 M(-0.2%) | -$43.00 M(-6.4%) |
Jun 2007 | - | -$10.75 M(-0.7%) | -$45.92 M(-2.5%) |
Mar 2007 | - | -$10.83 M(+1.3%) | -$47.08 M(+2.6%) |
Dec 2006 | -$46.62 M(+48.6%) | -$10.69 M(-21.8%) | -$45.88 M(-3.2%) |
Sep 2006 | - | -$13.66 M(+14.7%) | -$47.40 M(+16.7%) |
Jun 2006 | - | -$11.90 M(+23.6%) | -$40.60 M(+16.2%) |
Mar 2006 | - | -$9.63 M(-21.1%) | -$34.93 M(+13.8%) |
Dec 2005 | -$31.36 M(+131.0%) | -$12.20 M(+77.9%) | -$30.69 M(+66.0%) |
Sep 2005 | - | -$6.86 M(+10.1%) | -$18.49 M(+59.0%) |
Jun 2005 | - | -$6.23 M(+15.6%) | -$11.62 M(+115.6%) |
Mar 2005 | - | -$5.39 M | -$5.39 M |
Dec 2004 | -$13.58 M(+38.1%) | - | - |
Dec 2003 | -$9.83 M(+55.8%) | - | - |
Dec 2002 | -$6.31 M(-6.1%) | - | - |
Dec 2001 | -$6.72 M(+67.5%) | - | - |
Dec 2000 | -$4.01 M | - | - |
FAQ
- What is DexCom annual EBITDA?
- What is the all time high annual EBITDA for DexCom?
- What is DexCom annual EBITDA year-on-year change?
- What is DexCom quarterly EBITDA?
- What is the all time high quarterly EBITDA for DexCom?
- What is DexCom quarterly EBITDA year-on-year change?
- What is DexCom TTM EBITDA?
- What is the all time high TTM EBITDA for DexCom?
- What is DexCom TTM EBITDA year-on-year change?
What is DexCom annual EBITDA?
The current annual EBITDA of DXCM is $916.70 M
What is the all time high annual EBITDA for DexCom?
DexCom all-time high annual EBITDA is $916.70 M
What is DexCom annual EBITDA year-on-year change?
Over the past year, DXCM annual EBITDA has changed by +$351.40 M (+62.16%)
What is DexCom quarterly EBITDA?
The current quarterly EBITDA of DXCM is $237.40 M
What is the all time high quarterly EBITDA for DexCom?
DexCom all-time high quarterly EBITDA is $303.60 M
What is DexCom quarterly EBITDA year-on-year change?
Over the past year, DXCM quarterly EBITDA has changed by -$7.30 M (-2.98%)
What is DexCom TTM EBITDA?
The current TTM EBITDA of DXCM is $975.30 M
What is the all time high TTM EBITDA for DexCom?
DexCom all-time high TTM EBITDA is $1.03 B
What is DexCom TTM EBITDA year-on-year change?
Over the past year, DXCM TTM EBITDA has changed by -$56.10 M (-5.44%)